MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 415-421

  Amato, Robert J ^a   Stephenson, Joe ^b,f   Hotte, Sebastien ^c   Nemunaitis, John ^d   Bélanger, Karl ^e   Reid, Gregory ^f   Martell, Robert E ^g  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Cancer Treatment Center   (United States)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d Mary Crowley Medical Research Center   (United States)

^e NOTRE DAME HOSPITAL   (Canada)

^f METHYLGENE INC   (Canada)

^g TUFTS MEDICAL CENTER   (United States)

Author keywords

CpG; DNA methylation; DNMT; Interferon; Kidney cancer; MG98; Tumor suppressor gene

Indexed keywords

ALPHA2B INTERFERON; MG 98;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; THIONUCLEOTIDES;

EID: 84861048806     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.675381     Document Type: Article

References (31)

1. Jemal A, Siegel R,WardE,MurrayT, Xu J,ThunMJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Costa LJ, DrabkinHA. Renal cell carcinoma: newdevelopments in molecular biology and potential for targeted therapies.Oncologist 2007;12:1404-1415.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-321. (Pubitemid 23154480)
4. Bleumer I, Oosterwijk E, DeMulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65-75. (Pubitemid 36741377)
5. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A,Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007;25(18S):5033.
6. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; ebpub 20 Mar.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007;25(18S):241S.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007;356:125-134.
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New J Med 2003;349:427-434. (Pubitemid 36910021)
10. Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Moore N. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as firstline therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25(18S):3.
11. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(3):475-480.
12. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003;349:2042-2054. (Pubitemid 37448928)
13. Szyf M.TheDNAmethylation machinery as a target for anticancer therapy. PharmacolTher 1996;70:1-37. (Pubitemid 26175238)
14. MacLeod RA, Rouleau J, Szyf M. Regulation of DNA methylation status by the ras signaling pathway. J Biol Chem 1995;270:11327-11337.
15. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-65. (Pubitemid 36068683)
16. Kautiainen TL, Jones PA. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 1996;261:1594-1598.
17. Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 1994;15:233-238. (Pubitemid 24210728)
18. Battaglia C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695-8699. (Pubitemid 38064046)
19. Yeivin A, RazinA.Genemethylation patterns and expression. EXS 1993;64:523-568.
20. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-556. (Pubitemid 34288859)
21. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003-1007. (Pubitemid 30243595)
22. Agrawal S, Iyer RP. Perspectives in antisense therapeutics. PharmacolTher 1997;76:151-160. (Pubitemid 28078568)
23. Frederic J. Reu, Mark W. Fox, Mamta Chawla-Sarkar, Normand Beaulieu, Douglas W. Leaman, A. Robert Macleod, Ernest C. Borden. Genes involved in sensitization of renal cancer cells to interferon-induced apoptosis after selective depletion of DNA methyltransferase-1 by antisense oligonucleotide (MG98). Proc Amer Assoc Cancer Res. Volume 45, 2004. Abstract #1609.
24. Reu FJ, Beaulieu N, Mama CS, Macleod RA, Borden EC. Selective depletion of DNA methyltransferase-1 by antisense (MG98) sensitized renal cancer cells to interferon-induced apoptosis. Clin Cancer Res 2003;9 (December Suppl. 16): Abstract #167.
25. TherasseP, ArbuckSG,EisenhauerEA,Wanders J,KaplanRS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, ChristianMC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
26. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer res 2003;63:8695-8699. (Pubitemid 38064046)
27. Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR.The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'deoxycytidine. Clin Cancer Res 2004;10:7011-7021. (Pubitemid 39383053)
28. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour spuppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-209. (Pubitemid 28262196)
29. Herman JG, Latif F,Weng Y, LermanMI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;9700-9704. (Pubitemid 24311875)
30. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S. Regional DNA hypermethylation and DNA methyltranserase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006;119:288-296.
31. Agrawal S, Iyer RP. Perspectives in antisense therapeutics. PharmacolTher 1997;76:151-160. (Pubitemid 28078568)